Selected antileukemic drugs being tested in clinical trials.
| Drug . | Mechanism of action . | Subtype of leukemia targeted . |
|---|---|---|
| Adapted and reproduced with permission Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043.1 | ||
| Clofarabine | Inhibits DNA polymerase and ribonucleotide reductase; disrupts mitochondria membrane | All |
| Nelarabine | Inhibits ribonucleotide reductase and DNA synthesis | T-cell |
| Forodesine | Inhibits purine nucleoside phosphorylase | T-cell |
| γ-secretase inhibitors | Inhibit γ-secretase, an enzyme required for NOTCH1 signaling | T-cell |
| Rituximab | Anti-CD20 chimeric murine-human monoclonal antibody | CD20-positive |
| Epratuzumab | Anti-CD22 humanized monoclonal antibody | CD22-positive |
| Alemtuzumab | Anti-CD52 humanized monoclonal antibody | CD52-positive |
| Gemtuzumab ozogamicin | Anti-CD33 monoclonal antibody conjugated with calicheamicin | CD33-positive |
| Imatinib mesylate | ABL kinase inhibition | BCR-ABL-positive |
| Nilotinib | ABL kinase inhibition | BCR-ABL-positive |
| Dasatinib | BCR-ABL kinase inhibition | BCR-ABL-positive |
| Lestaurtinib; midostaurin; tandutinib; sunitinib hyperdiploid | IMC-EB10 FMS-like tyrosine kinase 3 inhibition | MLL-rearranged; maleate |
| Tipifarnib; lonafarnib | Farnesyltransferase inhibition | All |
| Azacytidine; decitabine; temozolomide | DNA methyltransferase inhibition | All |
| Romidepsin; vorinostat; valproic acid; MD-27–275; AN-9 | Histone deacetylase inhibition | All |
| Sirolimus; temsirolimus; everolimus; AP-23573 | Mammalian target of rapamycin inhibition | All |
| Bortezomib | Inhibition of ubiquitin proteasome pathway | All |
| Flavopiridol | Serine-threonine cyclin-dependent kinase inhibition | All |
| Oblimersen | Downregulation of BCL2 | All |
| 17-AAG | Heat shock protein-90 inhibitor | BCR-ABL-positive; ZAP-70-positive |
| Drug . | Mechanism of action . | Subtype of leukemia targeted . |
|---|---|---|
| Adapted and reproduced with permission Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043.1 | ||
| Clofarabine | Inhibits DNA polymerase and ribonucleotide reductase; disrupts mitochondria membrane | All |
| Nelarabine | Inhibits ribonucleotide reductase and DNA synthesis | T-cell |
| Forodesine | Inhibits purine nucleoside phosphorylase | T-cell |
| γ-secretase inhibitors | Inhibit γ-secretase, an enzyme required for NOTCH1 signaling | T-cell |
| Rituximab | Anti-CD20 chimeric murine-human monoclonal antibody | CD20-positive |
| Epratuzumab | Anti-CD22 humanized monoclonal antibody | CD22-positive |
| Alemtuzumab | Anti-CD52 humanized monoclonal antibody | CD52-positive |
| Gemtuzumab ozogamicin | Anti-CD33 monoclonal antibody conjugated with calicheamicin | CD33-positive |
| Imatinib mesylate | ABL kinase inhibition | BCR-ABL-positive |
| Nilotinib | ABL kinase inhibition | BCR-ABL-positive |
| Dasatinib | BCR-ABL kinase inhibition | BCR-ABL-positive |
| Lestaurtinib; midostaurin; tandutinib; sunitinib hyperdiploid | IMC-EB10 FMS-like tyrosine kinase 3 inhibition | MLL-rearranged; maleate |
| Tipifarnib; lonafarnib | Farnesyltransferase inhibition | All |
| Azacytidine; decitabine; temozolomide | DNA methyltransferase inhibition | All |
| Romidepsin; vorinostat; valproic acid; MD-27–275; AN-9 | Histone deacetylase inhibition | All |
| Sirolimus; temsirolimus; everolimus; AP-23573 | Mammalian target of rapamycin inhibition | All |
| Bortezomib | Inhibition of ubiquitin proteasome pathway | All |
| Flavopiridol | Serine-threonine cyclin-dependent kinase inhibition | All |
| Oblimersen | Downregulation of BCL2 | All |
| 17-AAG | Heat shock protein-90 inhibitor | BCR-ABL-positive; ZAP-70-positive |